Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 14/20 | 0.57 |
| ▸ | ADRB1 | P08588 | 9/20 | 0.57 |
| ▸ | ADRB3 | P13945 | 7/20 | 0.57 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.40 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.33 |
| ▸ | BCHE | P06276 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2795663 | 0.87 | ADRB2 (0.45) | ADRB2ADRB1ADRB3BCHEMEN1 | |
| SCHEMBL2795662 | 0.87 | ADRB2 (0.45) | ADRB2ADRB1ADRB3BCHEMEN1 | |
| SCHEMBL2009303 | 0.85 | ADRB2 (0.44) | ADRB2ADRB1ADRB3BCHEMEN1 | |
| SCHEMBL2009306 | 0.85 | ADRB2 (0.44) | ADRB2ADRB1ADRB3BCHEMEN1 | |
| SCHEMBL2009305 | 0.85 | ADRB2 (0.44) | ADRB2ADRB1ADRB3BCHEMEN1 | |
| SCHEMBL2012558 | 0.83 | ADRB2 (0.56) | ADRB2ADRB1ADRB3 | |
| SCHEMBL2012556 | 0.83 | ADRB2 (0.56) | ADRB2ADRB1ADRB3 | |
| SCHEMBL2012553 | 0.83 | ADRB2 (0.56) | ADRB2ADRB1ADRB3 | |
| SCHEMBL2748417 | 0.81 | ADRB2 (0.45) | ADRB2ADRB1ADRB3MEN1KMT2A | |
| SCHEMBL2791899 | 0.81 | ADRB2 (0.43) | ADRB2ADRB1ADRB3BCHEMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120071654-A1 | ARYL ANILINE DERIVATIVES AS BETA2 ADRENERGIC RECEPTOR AGONISTS | THERAVANCE, INC. (US) | 2012-03-22 | — | — | US | disclosed |
| US-7994165-B2 | Aryl aniline derivatives as β2 adrenergic receptor agonists | THERAVANCE, INC. (US) | 2011-08-09 | — | — | US | disclosed |
| EP-1706371-B1 | ARYL ANILINE DERIVATIVES AS BETA2 ADRENERGIC RECEPTOR AGONISTS | THERAVANCE INC (US) | 2011-04-06 | — | — | EP | disclosed |
| US-20100087410-A1 | ARYL ANILINE DERIVATIVES AS BETA2 ADRENERGIC RECEPTOR AGONISTS | THERAVANCE, INC. (US) | 2010-04-08 | — | — | US | disclosed |
| US-7622467-B2 | 5-[(R)-2-(2-{4-[4-(2-amino-2-methyl-propoxy)-phenylamino]-phenyl}-ethylamino)-1-hydroxy-ethyl]-8-hydroxy-1H-quinolin-2-one; extended duration of action; potency, selectivity; asthma, chronic obstructive pulmonary disease, antiinflammatory, pre-term labor, neurological and cardiac disorders | THERAVANCE, INC. (US) | 2009-11-24 | — | — | US | disclosed |
| EP-1706371-A1 | ARYL ANILINE DERIVATIVES AS BETA2 ADRENERGIC RECEPTOR AGONISTS | Theravance, Inc. (US) | 2006-10-04 | — | — | EP | disclosed |
| WO-2005070872-A1 | ARYL ANILINE DERIVATIVES AS BETA2 ADRENERGIC RECEPTOR AGONISTS | THERAVANCE, INC. (US) | 2005-08-04 | — | — | WO | disclosed |
| US-20050159448-A1 | Aryl aniline derivatives as beta2 adrenergic receptor agonists | THERAVANCE, INC. | 2005-07-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120071654-A1 | ARYL ANILINE DERIVATIVES AS BETA2 ADRENERGIC RECEPTOR AGONISTS | ADRB2, ADRB1, ADRA2A | ADRB2 1/4885ADRB1 2/4885ADRB3 4/4885 |
| US-20050159448-A1 | Aryl aniline derivatives as beta2 adrenergic receptor agonists | ADRB2, ADRB1, ADRA2A | ADRB2 1/4885ADRB1 2/4885ADRB3 4/4885 |
| US-20100087410-A1 | ARYL ANILINE DERIVATIVES AS BETA2 ADRENERGIC RECEPTOR AGONISTS | ADRB2, ADRB1, ADRA2A | ADRB2 1/4885ADRB1 2/4885ADRB3 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.